Vactosertib for recurrent or progressive bone cancer
Part of Cancer clinical trials.
This trial tests a new drug called vactosertib for people with a type of bone cancer called osteosarcoma that has come back or hasn't responded to other treatments. The goal is to see if the drug can help shrink or slow the cancer and to check its safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 12 years old.
- You must have osteosarcoma (a type of bone cancer) that has come back or continues to grow despite treatment.
- Your cancer must be measurable on scans (meaning it can be seen and tracked).
- You must have recovered from the side effects of previous cancer treatments, with most side effects being mild (like hair loss or mild tiredness).
- You must have adequate organ function, including bone marrow, liver, and heart function. This will be checked with blood tests and heart tests.
- You must be well enough to care for yourself (ECOG performance status 0-2) or, if under 16, have an equivalent score.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a pill called sulfatinib for young people with bone cancer (osteosarcoma) that has come back or not responded to standard treatments. Sulfatinib works by cutting off the blood supply that tumors need to grow, and the goal is to see if it can control the cancer.
This trial tests a combination of two drugs, losartan and sunitinib, in people with osteosarcoma that has come back or spread after prior treatment. The study aims to see if this combination is safe and effective.
This trial combines four targeted drugs (gefitinib, trametinib, disulfiram, sunitinib) with standard chemotherapy to treat osteosarcoma that has spread or come back. The goal is to see if this drug mix helps shrink tumors or keep them from growing.
This trial tests a new drug called OMO-103, which targets a protein called Myc that helps cancer cells grow. It is for people with advanced osteosarcoma (bone cancer) that has worsened after standard chemotherapy. The drug is given intravenously (through a vein), and the study will check if it is safe and shrinks tumors.
This Phase 2 trial studies HS-20093 in adults with osteosarcoma or other sarcomas that came back or did not respond to standard treatment. It aims to see how well the drug works and whether it is safe for people whose cancer has progressed.
This trial studies a new combination of two drugs, domatinostat and sirolimus, for people with sarcoma or osteosarcoma that hasn't improved after standard treatments. The goal is to see if this combination can help shrink or slow the cancer.
Hear when a new Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.